Telephone: +44 (0)1304 616161



Worldwide Biopharmaceutical Businesses

Date: 11th March 2020

DIRECT HEALTHCARE PROFESSIONAL COMMUNICATION

Ativan 4mg/ml Solution for Injection (Lorazepam): **Interim Supply of Irish Stock to Mitigate Supply Disruption**

Dear Healthcare Professional,

Summary: Pfizer is currently experiencing supply disruption with Ativan 4mg/ml Solution for injection in the UK.

To ensure continuity in supply, Pfizer has obtained approval from the MHRA to supply Irish product (batch number 4102).

Please note the following:

- The product from Ireland is manufactured according to the same manufacturing process and quality controls as the UK product.
- The benefit-risk profile is consistent with the UK formulation.
- There are minor differences between the Irish and UK product information. Please ensure UK Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL) are followed.
- For further details on the product please refer to the attached UK approved Patient Information Leaflet provided in the polythene bag with the Irish pack. Discard the Irish leaflet in the pack.

Further information

Please refer to the Summary of UK Product Characteristics (SPC) for further details. https://www.medicines.org.uk/emc/product/5473/smpc

Please ensure all relevant staff are made aware of the content of this letter and that the information is communicated to the patients.

Call for reporting

Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Company contact point

If you have any questions about this letter or for more information about Ativan, please contact Pfizer Medical Information at Pfizer Limited, Walton Oaks, Dorking Road, Tadworth, Surrey, KT20 7NS or Telephone: 01304 616 161 or www.pfizermedicalinformation.co.uk/.

Yours faithfully,

Greg Coates

Medical Affairs, Internal Medicine, Pfizer Ltd